Gland Pharma announced strong Q3 FY26 results with revenue up 22% year-over-year and adjusted PAT growth of 37%. Key performance indicators include robust revenue, strong adjusted EBITDA margin, and consistent execution across the business. The company anticipates sustaining this growth through new product launches, CDMO contract ramp-ups and improved operational efficiencies.
Financial Performance Highlights
Gland Pharma (BSE: 543245 | NSE: GLAND) reported a 22% year-on-year increase in revenue and a 37% increase in adjusted PAT for Q3 FY26. The company’s performance was driven by consistent execution and double-digit growth in key markets, particularly in the U.S. and Europe. Key highlights from the consolidated financial performance include:
- Revenue from operations: ₹16,954 million, a 22% increase year-over-year
- Adjusted EBITDA: ₹4,490 million, with a margin of 26%
- Adjusted PBT: ₹3,865 million, a 29% increase year-over-year
- Adjusted PAT: ₹2,797 million, a 37% increase year-over-year
Segmental Performance
The company’s base business (Gland) showed robust growth, with revenue increasing by 16% year-over-year. Key metrics for the base business include:
- Revenue from operations: ₹11,790 million, up 16% year-over-year
- Adjusted EBITDA margin: 37%
- Adjusted PAT: ₹3,274 million, up 14% year-over-year
Cenexi’s performance also contributed significantly to the consolidated results. Key metrics include:
- Revenue from operations: €50 million, a 39% increase year-over-year
Strategic Developments
Gland Pharma continues to focus on strategic initiatives to drive growth, including:
- R&D investments: Increased to ₹650 million, representing 5.4% of revenue
- New launches: Nine molecules launched in the U.S. during the quarter
- New CMO contract: Signed with a large pharmaceutical company for a complex Nano Drug Delivery System based Injectable contract in Oncology
Market-wise Performance
The company experienced growth across various geographical markets:
- USA: Revenue increased by 19% to ₹8,685 million
- Europe: Revenue increased significantly by 54% to ₹4,071 million
- India: Increased by 32% to ₹744 million
Source: BSE
